Insud Pharma
Sudheer Reddy Kundla is a highly experienced professional in the field of quality assurance within the pharmaceutical industry, currently serving as a Global GMP Quality Auditor at Insud Pharma since January 2025, focusing on the APAC region. Prior roles include Corporate Quality Assurance Manager at Curia, Deputy Manager Quality Assurance and Assistant Manager QA at Insud Pharma, and Assistant Manager - CQA at Cipla, where Sudheer managed various aspects of quality operations, technology transfer, and compliance. Experienced at Annora Pharma, Epione Labs, Pulse Pharmaceuticals, and Shaun Pharmaceutical, Sudheer has developed a rich background in third-party quality operations, audit compliance, and quality management systems, complemented by a Bachelor of Pharmacy obtained from Prrm College of Pharmacy.
This person is not in any teams
This person is not in any offices
Insud Pharma
5 followers
INSUD PHARMA operates across the entire pharmaceutical value chain, delivering specialized expertise and experience in scientific research, development, manufacturing, sales and marketing of a wide range of value-adding active pharmaceutical ingredients (APIs), finished dosage forms (FDFs) and branded pharmaceuticals, for human and animal health. While the main offices are located in Madrid, Lugano, Buenos Aires, INSUD PHARMA is acting worldwide, creating a broad and balanced manufacturing and commercial network across Europe, America, Asia and Africa, to address global opportunities and customers` needs in all major pharmaceutical markets. INSUD PHARMA's activity is organized in three synergistic business areas: Industrial (Chemo), Branded (Exeltis) and Biotech (mAbxience), with over 7,300 professionals in more than 50 countries, 18 state-of-the-art facilities, 15 specialized R&D centers, 12 commercial offices and more than 35 pharmaceutical affiliates, serving 1,150 customers in 96 countries around the world. INSUD PHARMA believes in innovation and sustainable development. Our commitment is to improve people`s health and quality of life, providing access to quality medicines at affordable prices, and to continuously expand our efforts and R&D investment to develop new and better therapies.